| Filed Pursuant to Rule 424(b)(3) | ||
| Registration No. 333-163704 |
PROSPECTUS SUPPLEMENT NO. 6
(To prospectus dated January 26, 2010,
as supplemented by Supplement No. 1, dated May 27, 2010,
as supplemented by Supplement No. 2, dated June 24, 2010,
as supplemented by Supplement No. 3, dated August 11, 2010,
as supplemented by Supplement No. 4, dated August 17, 2010
as supplemented by Supplement No. 5, dated September 20, 2010)
119,512,556 Ordinary Shares
AMARIN CORPORATION PLC
This prospectus supplement no. 6 (this “Supplement”) supplements and amends the prospectus dated January 26, 2010 (as amended by prospectus supplement no. 1, dated May 27, 2010, by prospectus supplement no. 2, dated June 24, 2010, by prospectus supplement no. 3, dated August 11, 2010, by prospectus supplement no. 4, dated August 17, 2010, and by prospectus supplement no. 5, dated September 20, 2010 as so amended and supplemented, the “Prospectus”), which relates to the sale of up to 119,512,556 of our ordinary shares, par value £0.50 per share (“Ordinary Shares”), each represented by one American Depositary Share (“ADS”), of Amarin Corporation plc, by the selling shareholders named in the Prospectus or their transferees, pledgees, donees or other successors in interest. This Supplement does not relate to our issuance of additional Ordinary Shares or ADSs beyond the 119,512,556 originally covered by the Prospectus.
This Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus, which is to be delivered with this Supplement. This Supplement is qualified by reference to the Prospectus, except to the extent that the information in this Supplement updates and supersedes the information contained in the Prospectus.
Our ADSs are listed on the NASDAQ Capital Market, the principal trading market for our securities, under the symbol “AMRN.”
INVESTING IN THE SECURITIES INVOLVES RISKS. SEE “RISK FACTORS” BEGINNING ON PAGE 5 OF THE PROSPECTUS FILED ON JANUARY 26, 2010 AND ON PAGE 4 OF OUR ANNUAL REPORT ON FORM 20-F INCLUDED IN THE ABOVE-REFERENCED PROSPECTUS SUPPLEMENT NO. 2 TO READ ABOUT FACTORS YOU SHOULD CONSIDER BEFORE BUYING THESE SECURITIES. BEFORE BUYING THESE SECURITIES, YOU SHOULD READ AND CONSIDER THE INFORMATION THAT AMARIN CORPORATION PLC FILES WITH THE SECURITIES AND EXCHANGE COMMISSION.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this Supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus supplement no. 6 is October 22, 2010.
After 10 years of service with the Company, Mr. Thomas Lynch is resigning from the Company’s Board of Directors, effective October 18, 2010. His tenure with the Company included serving as Chairman and Chief Executive Officer and more recently overseeing the financing of AMR101’s Phase 3 clinical trials. In connection with these financing events, the Company re-focused its efforts on developing improved treatments for cardiovascular disease and certain executive functions were consolidated from multiple offices to the Company’s research and development headquarters in the United States. Mr. Lynch’s departure is amicable and he has offered to help the Company if and when needed.